The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease.
about
Measuring the impact of dermatological conditions on family and caregivers: a review of dermatology-specific instruments.Why quality of life measurement is important in dermatology clinical practice: An expert-based opinion statement by the EADV Task Force on Quality of Life.Condition-specific quality of life questionnaires for caregivers of children with pediatric conditions: a systematic review.A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases.Chronic diseases among vitiligo patients. A case control study.Quality-of-life outcomes and measurement in childhood atopic dermatitisAssessing quality of life in older adult patients with skin disorders.Identification of translational dermatology research priorities in the U.K.: results of an electronic Delphi exerciseBurden of skin diseases.The quantitative measurement of family quality of life: a review of available instruments.The Dermatitis Family Impact questionnaire: a review of its measurement properties and clinical application.Quality of life for parents of children with influenza-like illness: development and validation of Care-ILI-QoL.Conceptualisation, development and validation of T-QoL© (Teenagers' Quality of Life): a patient-focused measure to assess quality of life of adolescents with skin diseases.Quality of Life in Patients with Atopic Dermatitis: Disease Burden, Measurement, and Treatment Benefit.Review of Systemic Treatment Options for Adult Atopic Dermatitis.Broader concepts of quality of life measurement, encompassing validation.Psoriasis has a major secondary impact on the lives of family members and partners.Japanese version of the Family Dermatology Life Quality Index: Translation and validation.Impact of Cosmetic Camouflage on the Quality of Life of Children With Skin Disease and Their Families.Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study.The impact of influenza-like illness in young children on their parents: a quality of life survey.The evaluation of family impact of recessive dystrophic epidermolysis bullosa using the Italian version of the Family Dermatology Life Quality Index.Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases.Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (EADV) Task Force on quality of life.The significance of structured parental educational intervention on childhood atopic dermatitis: a randomized controlled trial.Quality of Life in Families with Children with Atopic Dermatitis.Comparison of the impairment of family quality of life assessed by disease-specific and dermatology-specific instruments in children with atopic dermatitis.Quality of life in dermatology: after 125 years, time for more rigorous reporting.The three dimensions of skin disease burden: 'now', 'long term' and 'family'.Preliminary reliability and validity of Persian version of the Family Dermatology Life Quality Index (FDLQI).Quality of life in family members of vitiligo patients: a questionnaire study in Saudi Arabia.The development and validation of the Family Reported Outcome Measure (FROM-16)© to assess the impact of disease on the partner or family member.The family impact of skin diseases: the Greater Patient concept.Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families?The impact of disease on family members: a critical aspect of medical care.Quality of life of dogs with skin disease and of their owners. Part 2: administration of a questionnaire in various skin diseases and correlation to efficacy of therapy.Measurement of family impact of skin disease: further validation of the Family Dermatology Life Quality Index (FDLQI).Quality of life of dogs with skin diseases and their owners. Part 1: development and validation of a questionnaire.The Greater Patient concept.Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial
P2860
Q30234733-2960F1D1-33AD-4A90-9A99-49BDEB5A5997Q30244189-584F2B01-3F1B-422E-8F80-D3580AC1D2A2Q31110421-404E1461-6D2D-47F6-8D72-35DA1CBEAD4BQ33402382-94CF35B1-4597-4DC9-A27D-E334163A1884Q33735253-C723E545-B06B-40F1-AB33-D8473A758449Q35148180-EEB05E13-872D-47D4-8D82-7E8BB1340280Q36648569-2880EE55-2791-4700-8234-EC3937A67F74Q37289465-B3A012E4-0767-4714-BFE5-0F3203DD1F74Q37519631-52DE1622-6CB5-457B-A969-900C80CCEAB3Q37924904-7F4519EE-BD8A-4132-8067-75D2E201C95CQ38119984-5878EDDC-6219-4382-B416-54858D8A1777Q38148075-DEB446FB-218A-4545-973A-53EE77C07E2DQ38649988-1AD1CDCF-683A-4BC8-BC34-BEE44EE75A2DQ38714120-5DD95D2A-E980-4F34-95A4-3CE335C0C685Q38956008-8DAD3FDC-4C7B-40A5-AAEA-3ED925CD61D5Q39215992-98A1D82B-63C4-4464-A77C-0C25717B629EQ40219748-DB6B5EFE-77CC-4A3B-82F2-ACE1511C62D3Q40278786-D5623E8D-D4E6-4EA9-B5F8-68B690C0D3F9Q40750109-551B343F-4C7F-4F1E-801A-A7BAB82D92B0Q41230071-17135AAC-11CC-4054-8DD1-F032C2B94C00Q45065084-1C3F8FD3-1664-4DFD-9D99-1470B86C9831Q45779234-AF725624-D9FC-4EAB-A7D0-51FD90508BF0Q47362617-68156884-77FB-499E-A23A-931F9C48E5D3Q47616404-7A587BBC-6A4C-4366-8BAE-C4BC22D3A518Q47913683-F6FC6C03-F939-41E3-97D7-2E5E606453E0Q47941875-985DD323-90F8-4CD7-8F7E-EC309C0093B8Q48071898-0A338D7E-B5F1-4907-BFFF-A1C4DCF16850Q48094134-2DD3F302-4ED9-45C0-B9FD-5070BD91387FQ48142648-4044DEE5-0BC1-43D2-A7F7-FBA19F279710Q48165367-33E27289-C253-4FEB-8388-82CDA72F99E7Q48209658-52A4FDA8-B0C0-40AE-809E-2503F5E25609Q48219375-AF1D1A4E-1A78-41D1-94E5-7B05433AAB76Q48473839-52118D24-E7A2-4CD1-8FDD-9BC4D5A27F23Q48708208-DDBD89D5-D0C4-40FD-925B-B2AF19C6753CQ50705384-0F665CFE-D7A3-4230-B70C-D54CEEC16729Q51487598-1E663FAA-1159-4A2C-A1BA-8BCE3CA0CC59Q51712498-C4BAAC65-9A94-425F-B604-9D26D0754599Q53045250-DD800C0D-9893-4795-9DBF-819882573AB3Q53171295-72A92261-1764-45BB-9CB7-59AB09749CABQ57178617-B8E6BB39-BF11-4BF7-BD33-9EF484726973
P2860
The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
The Family Dermatology Life Qu ...... ondary impact of skin disease.
@en
The Family Dermatology Life Qu ...... ondary impact of skin disease.
@nl
type
label
The Family Dermatology Life Qu ...... ondary impact of skin disease.
@en
The Family Dermatology Life Qu ...... ondary impact of skin disease.
@nl
prefLabel
The Family Dermatology Life Qu ...... ondary impact of skin disease.
@en
The Family Dermatology Life Qu ...... ondary impact of skin disease.
@nl
P2860
P1476
The Family Dermatology Life Qu ...... ondary impact of skin disease.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2133.2006.07617.X
P407
P577
2007-03-01T00:00:00Z